Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic Risk Factors for Thiopurine-Induced Leukopenia in Patients with Inflammatory Bowel Disease.

Yonsei medical journal - 1 Aug 2026

Boo Eun Kyung, Yu Jongwook, Oh Sohyung, Cheon Jae Hee, Kim Ju Han

Abstract excerpt

PURPOSE: Thiopurines remain an effective treatment for maintaining remission in inflammatory bowel disease (IBD), yet their use is often limited by thiopurine-induced leukopenia (TIL), a potentially life-threatening adverse effect. We aimed to investigate pharmacogenetic associations with TIL in patients with IBD. MATERIALS AND METHODS: We retrospectively analyzed 218 thiopurine-treated patients from two...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azathioprine
Share to Inflammatory Bowel Diseases
Share to Interleukin-6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukopenia

Share to Mercaptopurine

Share to Methyltransferases

Share to Pharmacogenetics

Share to Pyrophosphatases

Source

Open in PubMed Open full text

Identifiers

PMID: 42494268
DOI: 10.3349/ymj.2025.0364
PMCID: PMC13407061

Genes

IL6
NUDT15
TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic Risk Factors for Thiopurine-Induced Leukopenia in Patients with Inflammatory Bowel Disease.PMID 42494268Read ↗

Prevalence of NUDT15 Genetic Variants and Incidence of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients.Semantic proximity Read ↗

Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel DiseaseSemantic proximity Read ↗

NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.Semantic proximity Read ↗

Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease.Semantic proximity Read ↗

Combined Detection of NUDT15 Variants Could Highly Predict Thiopurine-induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease: A Multicenter Analysis.Semantic proximity Read ↗

Effects of various genetic polymorphisms on thiopurine treatment-associated outcomes for Korean patients with Crohn's disease.Semantic proximity Read ↗

NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India.Semantic proximity Read ↗

Role of Pharmacogenomics in the Efficacy and Safety of Thiopurines in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

An intronic FTO variant rs16952570 confers protection against thiopurine-induced myelotoxicities in multiethnic Asian IBD patients.Semantic proximity Read ↗

Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.Semantic proximity Read ↗

A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.